COMMERCIALLY
INSURED PATIENTS

For eligible patients with questions about commercial, private, or employer insurance, contact ArrayACTS

Array Co-Pay Savings Program

Commercially insured patients may be eligible for a $0 co-pay for a month’s supply of BRAFTOVI + MEKTOVI*

GOVERNMENT-
INSURED PATIENTS

For patients with commercial or government insurance like Medicare, Medicare Part D, and Medicaid, ArrayACTS™ may be able to help connect you with resources

Independent Co-pay
Assistance Foundations

ArrayACTS™ can provide you with a referral to independent co-pay assistance foundations, if you’re eligible

FOR MORE INFORMATION ABOUT ARRAY PATIENT ASSISTANCE OPTIONS, TALK TO YOUR DOCTOR OR CALL ArrayACTS™ AT 1-866-ARRAYCS (1-866-277-2927).

FOR MORE INFORMATION ABOUT ARRAY PATIENT ASSISTANCE OPTIONS, TALK TO YOUR DOCTOR OR CALL ArrayACTS™ AT 1-866-ARRAYCS ( 1-866-277-2927).

UNDER- AND
UNINSURED PATIENTS

For patients who do not have health insurance or who have health insurance but cannot afford their Array medicines

Patient Assistance Program

If you don’t have insurance or prescription drug coverage and cannot afford to pay for BRAFTOVI + MEKTOVI, Array may be able to help if you qualify. Call ArrayACTS™ at 1-866-ARRAYCS  (1-866-277-2927) for more information

FOR MORE INFORMATION ABOUT ARRAY PATIENT ASSISTANCE OPTIONS, TALK TO YOUR DOCTOR OR CALL ArrayACTS™ AT 1-866-ARRAYCS (1-866-277-2927).

*To qualify for the Array Co-Pay Savings Program, you must have commercial insurance, like a plan you have through your employer. If you have Medicare, Medicaid, or other public insurance, you are not eligible for this program. You must also meet other criteria. Please see the full terms and conditions for this program.

Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We can only refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.

If you have health insurance, you must have already tried other types of patient assistance to qualify for the Patient Assistance Program. This includes the Array Co-Pay Savings Program and support from independent co-pay assistance foundations. You must also meet specific financial criteria.

Co-Pay Savings Program Terms and Conditions

By using the Array Co-Pay Savings Program, the patient acknowledges and confirms that, at the time of usage, (s)he is currently eligible and meets the criteria set forth in the terms and conditions described.

This Co-Pay Savings Program is valid ONLY for patients with commercial (private or non-governmental) insurance who are taking the medication for a Food and Drug Administration (FDA)-approved indication. Patients using Medicare, Medicaid, or any other federal or state government-funded program to pay for their medications are not eligible. Patients who start utilizing their government coverage during their enrollment period will no longer be eligible for the program. Patients may pay as little as $0 per month and Array BioPharma will pay the remaining out-of-pocket cost up to a maximum of $25,000.00 per calendar year. Any costs exceeding the maximum of $25,000.00 are the responsibility of the patient.

This Co-Pay Savings Program is not health insurance or a benefit plan. Distribution or use of the Co-Pay Savings Program does not obligate use or continuing use of any specific product or provider. Patient or guardian is responsible for reporting the receipt of all Co-Pay Savings Program benefits or reimbursement received to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Co-Pay Savings Program, as may be required.

The Co-Pay Savings Program is not valid for medications the patient receives for free or that are eligible to be reimbursed by private insurance plans or other healthcare or pharmaceutical assistance programs that reimburse the patient in part or for the entire cost of his/her Array BioPharma medication. Patient, guardian, pharmacist, prescriber, and any other person using the Co-Pay Savings Program agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer.

The Co-Pay Savings Program will be accepted by participating pharmacies, physician offices, or hospitals. To qualify for the benefits of this Co-Pay Savings Program, the patient may be required to pay out-of-pocket expenses for each treatment. This Co-Pay Savings Program is only available with a valid prescription and cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription. Use of this Co-Pay Savings Program must be consistent with all relevant health insurance requirements and payer agreements. Participating patients, pharmacies, physician offices, and hospitals are obligated to inform third-party payers about the use of the Co-Pay Savings Program as provided for under the applicable insurance or as otherwise required by contract or law. The Co-Pay Savings Program may not be sold, purchased, traded, or offered for sale, purchase, or trade. The Co-Pay Savings Program is limited to 1 per person during this offer period and is not transferable. Program eligibility period is contingent upon patient’s ability to meet and maintain all requirements as set forth by the program. Array BioPharma may periodically verify eligibility and will terminate patients without obligation to pay claims if change to status is detected. This program is not valid where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents where applicable (e.g. MA, CA).

The patient must be 18 years or older to receive Co-Pay Savings Program assistance. This Co-Pay Savings Program is (1) void if reproduced; (2) void where prohibited by law; (3) only valid in the United States and Puerto Rico; (4) only valid for FDA-approved on-label indications of Array BioPharma products; and (5) expires on 12/31/2018. Healthcare providers may not advertise or otherwise use the program as a means of promoting their services or Array BioPharma’s products to patients. Array BioPharma reserves the right to rescind, revoke, amend, or terminate the program without notice at any time.

Important Safety Information and Indication

What is the most important information I should know about BRAFTOVI?

BRAFTOVI may cause serious side effects, including:

  • Risk of new skin cancers. BRAFTOVI, when used alone or with MEKTOVI, may cause skin cancers called cutaneous squamous cell carcinoma or basal cell carcinoma
  • Talk to your healthcare provider about your risk for these cancers

    Check your skin and tell your healthcare provider right away about any skin changes, including a new wart, skin sore or reddish bump that bleeds or does not heal, or change in size or color of a mole

    Your healthcare provider should check your skin before and during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers

    Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment

  • Bleeding problems. BRAFTOVI, when taken with MEKTOVI, can cause serious bleeding problems, including in your stomach or brain, that can lead to death. Call your healthcare provider and get medical help right away if you have any signs of bleeding, including: headaches, dizziness, or feeling weak; cough up blood or blood clots; vomit blood or your vomit looks like “coffee grounds”; red or black stools that look like tar
  • Eye problems. Tell your healthcare provider right away if you develop any of these symptoms of eye problems: blurred vision, loss of vision, or other vision changes; see colored dots; see halos (blurred outline around objects); eye pain, swelling, or redness
  • Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start and during your treatment to check your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, light-headed, dizzy, or if you feel your heart beating irregularly or fast

MEKTOVI may cause serious side effects, including:

  • Heart problems, including heart failure. Your healthcare provider should check your heart function before and during treatment. Call your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing; shortness of breath; swelling of your ankles and feet; feeling light-headed
  • Blood clots. MEKTOVI can cause blood clots in your arms or legs, which can travel to your lungs and can lead to death. Get medical help right away if you have the following symptoms: chest pain; sudden shortness of breath or trouble breathing; pain in your legs with or without swelling; swelling in your arms and legs; a cool, pale arm or leg
  • Eye problems. MEKTOVI can cause serious eye problems that might lead to blindness. Call your healthcare provider right away if you develop any of these symptoms of eye problems: blurred vision, loss of vision, or other vision changes; see colored dots; see halos (blurred outline around objects); eye pain, swelling, or redness
  • Lung or breathing problems. MEKTOVI can cause lung or breathing problems. Tell your healthcare provider if you have any new or worsening symptoms of lung or breathing problems, including: shortness of breath; cough
  • Liver problems. Your healthcare provider should perform blood tests to check your liver function before and during treatment. Tell your healthcare provider if you have any of the following signs and symptoms of a liver problem: yellowing of your skin or the white part of your eyes (jaundice); dark or brown (tea-colored) urine; nausea or vomiting; loss of appetite
  • Muscle problems (rhabdomyolysis). MEKTOVI can cause muscle problems that can be severe. Your healthcare provider should perform a blood test to check your levels of an enzyme in your blood called creatine phosphokinase (CPK) before and during treatment. Tell your healthcare provider right away if you develop any of these symptoms: weakness; muscle aches or pain; dark, reddish urine
  • Bleeding problems. MEKTOVI, when taken with BRAFTOVI, can cause serious bleeding problems, including in your brain or stomach, that can lead to death. Call your healthcare provider and get medical help right away if you have any signs of bleeding, including: headaches, dizziness, or feeling weak; cough up blood or blood clots; vomit blood or your vomit looks like “coffee grounds”; red or black stools that look like tar

The most common side effects of BRAFTOVI and MEKTOVI when taken in combination: fatigue, nausea, diarrhea, vomiting, pain or swelling of your joints, abdominal pain BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of BRAFTOVI and MEKTOVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Array BioPharma Inc. at 1-844-792-7729.

Before taking BRAFTOVI + MEKTOVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have had bleeding problems
  • have eye problems
  • have heart problems, including a condition called long QT syndrome
  • have been told that you have low blood levels of potassium, calcium, or magnesium
  • have liver or kidney problems
  • have had blood clots
  • have lung or breathing problems
  • have any muscle problems
  • have high blood pressure (hypertension)
  • are pregnant or plan to become pregnant. BRAFTOVI + MEKTOVI can harm your unborn baby.
    • Females who are able to become pregnant should use effective nonhormonal birth control (contraception) during treatment and for at least 30 days after the final dose. Birth control methods that contain hormones (such as birth control pills, injections, or transdermal systems) may not work as well during treatment with BRAFTOVI
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with BRAFTOVI + MEKTOVI
  • are breastfeeding or plan to breastfeed. Do not breastfeed during treatment and for 2 weeks after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.

Please see both full BRAFTOVI Prescribing Information, including Medication Guide, and full MEKTOVI Prescribing Information, including Patient Information for additional information.

Indications AND Usage

What is BRAFTOVI + MEKTOVI?

BRAFTOVI and MEKTOVI are prescription medicines used together to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • that has a certain type of abnormal “BRAF” gene

BRAFTOVI should not be used to treat people with wild-type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you. It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.

You are now leaving braftovimektovi.com

The link you have selected will take you to a website that is not owned or controlled by Array BioPharma. Array BioPharma makes no representation as to the accuracy of the information on sites we do not own or control and does not recommend or endorse content on any third-party websites. Your use of a third-party website is at your own risk and subject to the terms and conditions of that site.